1.

Study of lncRNAs expression profile in the response to biological drugs in Psoriatic Arthritis: MEG3 could be a potential genomic biomarker of therapy efficacy. De Benedittis, G., D’Antonio, A., Latini, A., (…), Chimenti, M.S., Borgiani, P.            2024    International Immunopharmacology 134, 112239

2.

Evaluation of diagnostic and therapeutic delay in patients with rheumatoid arthritis and psoriatic arthritis Iacovantuono, M., Ferrigno, S., Conigliaro, P., (…), Bergamini, A., Chimenti, M.S. 2024 Reumatismo 76(1), pp. 35-42

3.

The rs11568820 Variant in the Promoter Region of Vitamin D Receptor Gene Is Associated with Clinical Remission in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors Latini, A., De Benedittis, G., Conigliaro, P., (…), Ciccacci, C., Borgiani, P. 2024 Genes 15(2),234

4.

Impact of biological therapy in reducing the risk of arthritis development in inflammatory bowel diseases Fatica, M., Monosi, B., Conigliaro, P., (…), Calabrese, E., Chimenti, M.S. 2024 RMD Open 10(1),e003820

5.

The steroid-sparing effect of JAK inhibitors across multiple patient populations Conigliaro, P., Minerba, C., Vendola, A, Bergamini, A., Chimenti, M.S.    2024    Frontiers in Immunology 15,1376476